OR-AIRSHIP
Mobile app experience company Airship today announced that it has acquired Gummicube , the original App Store Optimization (ASO) innovator and the world’s #1 provider in helping more top 10 apps across categories succeed than any other company. By linking Gummicube's ASO technology and expertise with Airship's App Experience Platform (AXP), brands can now optimize value across the entire mobile app lifecycle, driving greater organic growth, ROAS, retention, loyalty and monetization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005529/en/
The acquisition combines the leading ASO platform with the leading mobile app experience platform to offer brands a single set of enterprise solutions that together offer app store optimization, customer journey orchestration, no-code native app experiences and app UX experimentation. Both Airship and Gummicube customers will quickly benefit from access to new technology and expanded expertise to bookend growth and retention by more efficiently and effectively addressing both sides of the mobile app value chain — attracting and growing more valuable app customers, then retaining and monetizing them.
Gummicube nearly doubled its revenue year-over-year, with nearly three-quarters of total revenue coming from enterprise brands, and plans to nearly double its staff in 2022 to support continued growth. All 80 Gummicube employees have joined Airship with co-founders Dave Bell and Anh Nguyen becoming VPs and co-general managers of the Gummicube division at Airship. Airship will continue to innovate and invest in Gummicube’s solutions, while empowering customers with richer cross-platform data to better inform each step of the mobile app journey, from the experiences new app customers receive, to the insights that drive the next wave of organic audience growth.
“Driving consumers to download an app is a critical first step, but keeping them engaged and maximizing value for everyone involved requires leveraging data to demonstrate customer respect and relevance with experiences that reward them for their loyalty,” said Brett Caine, CEO and president, Airship. “Together, Gummicube and Airship enable marketers, product owners and developers to optimize their entire mobile app experience — from the point of discovery to loyalty. This industry-first combination will drive greater app success for brands, and unlock huge value for our business.”
“Gummicube and Airship are both 100% dedicated to helping mobile apps succeed. Before today, brands had to find their own answers to the two most fundamental questions: one, how do I attract and grow more quality users; and two, how do I retain them and grow value for everyone involved,” said Dave Bell, CEO and co-founder, Gummicube. “Now, our combination will drive more measurable value for customers than anyone else. This has never been done before!”
Splitcube, Gummicube’s A/B testing platform, enables developers, marketers and brands to test every single one of their store listing assets to continually optimize conversion rates in the app stores. Gummicube’s DATACUBE aggregates billions of data points from the App Store and Google Play Store to visualize search and behavioral trends. DATACUBE helps app marketers understand how the app stores merchandise their apps and those of their competitors, to more quickly grow app audiences and market share by optimizing app visibility. These SaaS technologies are combined with the most experienced ASO team in the world, who can work hand in hand with clients to manage processes and measure success.
Peak Technology Partners served as the exclusive sell-side advisor in this transaction.
Airship is dedicating the month of June to #MAXMonth where there will be a wealth of content, events and resources to help brands master mobile app experiences and unlock more value by optimizing the full app lifecycle. Learn more here: https://www.airship.com/max-month/ .
Airship is a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category and the second highest score in the Current Offering category.
About Gummicube
Gummicube pioneered App Store Optimization for mobile apps in 2010, and today partners with app developers and CMOs to optimize mobile app marketing for the App Store and Google Play Store. Thousands of apps have leveraged Gummicube’s technology and expert services to continuously improve app visibility and store conversion rates to acquire more quality users and build better apps.
Gummicube is an Airship company. For more information on Gummicube's services, or to receive a live demo of DATACUBE or Splitcube, please visit http://www.gummicube.com/ .
About Airship
No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship.
From the beginning of apps, Airship powered the first commercial messages and then expanded its data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation and feature release management. Now, with the Airship App Experience Platform (AXP), business users can create and adapt native app experiences on their own — with no ongoing developer support or app update required.
Having powered trillions of mobile app interactions for thousands of global brands, Airship’s technology and deep industry expertise have enabled apps to become the digital center of customer experience, brand loyalty and monetization.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005529/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom